Compare EOLS & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EOLS | VSTM |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 454.4M | 395.4M |
| IPO Year | 2018 | 2011 |
| Metric | EOLS | VSTM |
|---|---|---|
| Price | $5.71 | $6.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $15.50 | ★ $16.50 |
| AVG Volume (30 Days) | 776.9K | ★ 3.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.23 | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $297,176,000.00 | $30,914,000.00 |
| Revenue This Year | $13.27 | $282.64 |
| Revenue Next Year | $17.62 | $72.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.61 | ★ 209.14 |
| 52 Week Low | $3.86 | $3.43 |
| 52 Week High | $10.20 | $11.25 |
| Indicator | EOLS | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 75.12 |
| Support Level | $4.02 | $5.53 |
| Resistance Level | $7.16 | $6.10 |
| Average True Range (ATR) | 0.33 | 0.43 |
| MACD | -0.17 | 0.17 |
| Stochastic Oscillator | 11.95 | 97.19 |
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.